Hernexeos Patient Assistance Program
Don’t let the high cost of brand HER2-targeted therapy disrupt your cancer treatment. We help eligible patients access Hernexeos through the manufacturer’s Patient Assistance Program for as little as $69.95 per month with our comprehensive advocacy service.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Hernexeos (please verify current FDA prescribing information — a newer HER2-targeted therapy) is offered under a manufacturer-sponsored Patient Assistance Program. HER2-targeted therapies (whether monoclonal antibody, antibody-drug conjugate, or tyrosine kinase inhibitor) are used in HER2-positive breast, gastric, biliary, colorectal, and other tumors.
- Without assistance, HER2-targeted therapies commonly run thousands to tens of thousands of dollars per treatment cycle.
- Through AffordMyPrescriptions, qualifying patients can access Hernexeos for a flat $69.95 per month.
- HER2-targeted therapy landscape: trastuzumab (Herceptin — brand; and biosimilars Kanjinti, Ontruzant, Trazimera, Herzuma, Ogivri), pertuzumab (Perjeta), T-DM1 (Kadcyla ADC), T-DXd (Enhertu ADC — now first-line metastatic HER2+ breast cancer; also active in HER2-low breast cancer), Phesgo (SC pertuzumab + trastuzumab), Herceptin Hylecta (SC trastuzumab), neratinib (Nerlynx oral), tucatinib (Tukysa oral), margetuximab (Margenza), zanidatamab (Ziihera). Precision oncology — validated HER2 status testing required.
What is Hernexeos Prescription Assistance Program?
The Hernexeos Patient Assistance Program is a manufacturer-sponsored initiative that helps eligible patients access this HER2-targeted therapy at little or no cost when they meet income, insurance, and clinical criteria. The program is free to apply for, but enrollment involves detailed applications, oncology coordination, HER2 status documentation, and ongoing renewal.
At AffordMyPrescriptions, our Patient Advocates handle the entire Hernexeos PAP enrollment for a flat $69.95 per month — so you never face a gap in your Hernexeos therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Hernexeos enrollment — so you never face a gap in your HER2-targeted therapy.
Pharmacy Price Comparison
- Without assistance, HER2-targeted therapies cost thousands per cycle. A Patient Assistance Program can offset costs if you qualify:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Enhertu (T-DXd alt ADC) | ~$14,000/cycle | Alt HER2 ADC |
| Cancer center pharmacy | varies | Save substantially |
| Community oncology | varies | Save substantially |
| Hospital outpatient | varies | Save substantially |
| 340B-eligible institution | varies | Save substantially |
| Trastuzumab biosimilar (alt) | ~$4,000/cycle | IV biosimilar alt |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Hernexeos — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Hernexeos Prescription Program?
The Hernexeos Patient Assistance Program is free to apply. Our $69.95 per month covers full advocacy. Trastuzumab biosimilars offer significant cost savings for HER2 monoclonal antibody therapy. Discuss the full range of HER2-targeted options with your oncology team.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Hernexeos assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Hernexeos is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Hernexeos:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still varies by product per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Hernexeos assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Hernexeos Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Hernexeos:
Please verify current Hernexeos prescribing information and indication with your oncology team. HER2-targeted therapies work by inhibiting HER2 receptor signaling and/or delivering a cytotoxic payload to HER2-overexpressing tumor cells. Precision therapy requires validated HER2 status.
How It Works:
HER2 (human epidermal growth factor receptor 2) is a cell surface receptor tyrosine kinase overexpressed or amplified in a subset of breast cancer (~15–20%), gastric/GE junction cancer, biliary tract cancer, colorectal cancer, and other tumors. HER2 amplification drives proliferation and portends aggressive disease without targeted therapy. HER2-targeted therapies work by multiple mechanisms: monoclonal antibodies (trastuzumab, pertuzumab) block HER2 signaling and mediate ADCC; antibody-drug conjugates (Kadcyla — T-DM1, Enhertu — T-DXd) deliver a cytotoxic payload; tyrosine kinase inhibitors (neratinib, tucatinib) block HER2 kinase intracellularly; bispecific antibodies (Ziihera — zanidatamab) engage multiple HER2 epitopes. Precision oncology built on validated HER2 status (IHC and/or FISH). Verify Hernexeos current indication and prescribing details with your team.
Form and Use:
Please verify Hernexeos current dosing, administration route, and schedule with your oncology team. HER2 status testing (IHC and/or FISH) validation is typically required before therapy.
Generic Availability:
No generic Hernexeos. HER2-targeted therapy landscape: trastuzumab (Herceptin brand and Kanjinti, Ontruzant, Trazimera, Herzuma, Ogivri biosimilars — IV; and Herceptin Hylecta SC), Phesgo (SC pertuzumab + trastuzumab + hyaluronidase), Perjeta (pertuzumab), Kadcyla (T-DM1 ADC), Enhertu (T-DXd ADC — now first-line metastatic HER2+ breast cancer, and active in HER2-low), Nerlynx (neratinib oral), Tukysa (tucatinib oral), Margenza (margetuximab), Ziihera (zanidatamab — bispecific), and others. Susan G. Komen and other advocacy resources for breast cancer.
Warnings:
Please verify current Hernexeos prescribing information for boxed warnings and precautions. HER2-targeted therapies commonly carry warnings for cardiotoxicity (LVEF decline), pulmonary toxicity, infusion reactions, and embryo-fetal toxicity (contraindicated in pregnancy — HER2 is essential for fetal development). Standard HER2-targeted therapy precautions apply. Oncology and cardiology coordination for LVEF monitoring where appropriate.
FAQ (Frequently Asked Questions)
How much does Hernexeos cost without insurance?
Please verify current Hernexeos pricing at specialty pharmacies. HER2-targeted therapies commonly range from thousands (trastuzumab biosimilars) to tens of thousands (newer ADCs like Enhertu) per treatment cycle. Patient Assistance Programs are essential for uninsured patients.
How does Hernexeos fit into HER2-targeted therapy?
HER2-targeted therapies work through diverse mechanisms: monoclonal antibodies, antibody-drug conjugates, tyrosine kinase inhibitors, and bispecific antibodies. Please verify the Hernexeos indication and mechanism with your oncology team — the field is evolving rapidly.
Do I need HER2 testing before Hernexeos?
Yes — HER2 status validation (IHC and/or FISH) is standard before initiating any HER2-targeted therapy. Some newer therapies (Enhertu) also work in HER2-low disease. Your oncologist orders testing.
What HER2-targeted therapy alternatives exist?
Trastuzumab and biosimilars (IV and SC), Perjeta (pertuzumab), Phesgo (SC combo), Kadcyla (T-DM1 ADC), Enhertu (T-DXd ADC — first-line metastatic HER2+ breast), Nerlynx (neratinib oral), Tukysa (tucatinib oral), Margenza, Ziihera (zanidatamab). Extensive HER2-targeted options for various tumor types and lines of therapy.
What are Hernexeos side effects?
Please review current Hernexeos prescribing information for the specific side effect profile. HER2-targeted therapies commonly have cardiotoxicity (LVEF monitoring), infusion reactions, GI symptoms (varies by product), and fatigue. Some newer ADCs carry interstitial lung disease/pneumonitis risk requiring imaging surveillance.
Take Control of Your Medication Costs
HER2-targeted therapy transformed care for HER2-positive cancers. Our advocacy team is ready — $69.95 per month, or free if we cannot help.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.